No business profile yet.
Size Grape King Bio (1707.TW) is a Taiwan Health Care company (Pharmaceuticals: Other) with a market value of $342M, the 578th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$78.20 on 18 Nov 2026.
Performance Over six months the shares fell 27.3%, against -22.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 5.4% over the last twelve months (peer median -2.8%); the operating margin is 19.3% (peer median 8.5%).
Valuation It trades at 9.7× forward earnings against a peer median of 16.2× (3rd cheapest of 8).
Price implies For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -19 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.2 points above its cost of capital (5.0% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$9.84B | NT$10.3B | NT$11.2B | NT$10.6B | NT$10.4B |
| Revenue growth | — | -8% | +5% | +2% | — |
| Gross profit | NT$6.93B | NT$7.44B | NT$8.42B | NT$8.31B | NT$8.27B |
| EBITDA | NT$2.45B | NT$2.69B | NT$3.01B | NT$2.95B | NT$3.00B |
| Net income | NT$1.06B | NT$1.22B | NT$1.45B | NT$1.45B | NT$1.46B |
| Free cash flow | NT$1.25B | NT$1.73B | NT$1.25B | NT$1.93B | NT$2.50B |
| Capital expenditure | NT$442M | NT$464M | NT$648M | NT$602M | NT$502M |
| Total debt | NT$201M | NT$215M | NT$161M | NT$193M | NT$158M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1707.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.4% | -11.4% | 10th highest of 21 |
| 6-month return | -27.3% | -22.1% | 6th lowest of 21 |
| Distance from 52-week high | -39.9% | -43.8% | 8th highest of 21 |
| Revenue growth (TTM) | -5.4% | -2.8% | 8th lowest of 19 |
| Operating margin | 19.3% | 8.5% | 6th highest of 21 |
| Forward P/E | 9.7× | 16.2× | 3rd cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | -17.2% | 1.4% | least demanding of 14 |
| Growth delivered (Del g) | +2.3% | +5.6% | 6th lowest of 13 |
| Hurdle (Req g minus delivered) | -19.4 pp | -1.0 pp | 2nd least demanding of 13 |
| ROIC minus cost of capital | +9.2 pp | -0.1 pp | 7th highest of 20 |
| EV / EBITDA | 4.1× | 5.2× | 2nd cheapest of 5 |
| Net debt / EBITDA | -1.1× | -2.5× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Grape King Bio 1707.TW | Taiwan | $342M | -27% | -5% | 19% | 9.7× | -17.2% | +2.3% |
| Daiken Biomedical 7780.TW | Taiwan | $342M | -19% | n/a | 18% | n/a | -1.6% | n/a |
| Zhejiang Xinguang Pharmaceutical 300519.SZ | China | $319M | -15% | +5% | 27% | n/a | 3.1% | -1.3% |
| Boiron BOI.PA | France | $367M | -31% | -2% | 5% | 9.3× | -0.8% | -0.5% |
| TCI 8436.TWO | Taiwan | $312M | -24% | -4% | 18% | 9.9× | -12.1% | -3.2% |
| Weihai Baihe Biology Technological 603102.SS | China | $296M | -22% | +18% | 14% | 16.5× | -11.8% | +9.6% |
| Tibet Aim Pharm 002826.SZ | China | $407M | -22% | +13% | 14% | n/a | 0.4% | +1.0% |
| Myung in Pharm 317450.KS | South Korea | $466M | -20% | +7% | 35% | n/a | n/a | n/a |
| Lionco Pharmaceutical 603669.SS | China | $474M | +4% | -6% | -17% | n/a | n/a | n/a |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $532M | -2% | -4% | 21% | n/a | 1.4% | +7.0% |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $548M | -9% | +6% | 6% | n/a | 15.4% | +6.5% |
| ArriVent BioPharma AVBP | United States | $564M | -60% | n/a | -3,620% | n/a | n/a | n/a |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $583M | -23% | +21% | 11% | 45.4× | 19.1% | +12.1% |
| ABA Chemicals 300261.SZ | China | $592M | -26% | -16% | -23% | 405.0× | n/a | n/a |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $613M | -30% | 0% | 0% | n/a | n/a | n/a |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $641M | -22% | -28% | -25% | n/a | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $668M | -33% | +8% | 4% | n/a | 4.0% | +13.5% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $703M | -20% | -14% | 22% | n/a | 0.4% | +4.8% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $718M | -36% | -12% | 3% | n/a | 2.1% | -1.3% |
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 16.2× | 14.1% | +15.6% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | 7.6× | n/a | n/a |